Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE
Status:
Recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
A combination therapy proposed to be evaluated in this trial, consisting of three already
registered compounds with a validated disease mechanism and with known safety profiles,
targets key proteins in the dysregulated signal network in stroke, and is expected to
synergistically result in post-stroke blood-brain barrier stabilization and neuroprotection.
The synergistic mode of action will allow for low doses and is expected to reduce possible
side effects while maintaining maximal efficacy